Compare Dell Technologies Inc (DELL) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dell Technologies Inc vs Pfizer Inc — how do they compare? Dell Technologies Inc trades at $581 (market cap $365.31B), while Pfizer Inc trades at $27.73 (market cap $158.56B). The key difference: Dell Technologies Inc is far larger — about 2.3× Pfizer Inc's market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Dell Technologies Inc for 57 Days and Pfizer Inc for 158 Days on average.
| DELL | PFE | |
|---|---|---|
Market Cap | $365.31B | $158.56B |
Volume | 5,121,365 | 44,138,282 |
Sector | Technology | Health |
52-Week High | $588.67 | $29.02 |
52-Week Low | $111.10 | $23.67 |
Typical Hold Time | 57 Days | 158 Days |
Enterprise Value | $388.20B | $210.06B |
Dividend Yield | 0.44% | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dell Technologies trades at $578.96, up 0.9% with strong bullish momentum driven by AI server demand. The stock shows robust technical positioning above key support levels with a bullish moving average signal. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $7.04 surpassing estimates by 43%. The company raised its fiscal 2027 AI server revenue forecast to $74 billion, reflecting strong business momentum and operational discipline.
Dell presents compelling growth prospects with AI server backlog reaching $95 billion and raised revenue guidance. However, investors should monitor execution risks in scaling AI infrastructure and competitive pressures. The stock trades at a premium valuation (P/E 33.68) that requires sustained earnings growth. Analyst consensus remains bullish with 55.6% buy ratings and $566.35 price target.
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dell Technologies Inc
VMware is an industry titan in virtualizing IT infrastructure and became a stand-alone entity after spinning off from Dell Technologies in November 2021. The software provider operates in the three segments: licenses
Read more on DELL →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
